CHF6001 I: A Novel Highly Potent and Selective Phosphodiesterase 4 Inhibitor with Robust Anti-Inflammatory Activity and Suitable for Topical Pulmonary Administration-Reference-Cited by-同舟云学术

CHF6001 I: A Novel Highly Potent and Selective Phosphodiesterase 4 Inhibitor with Robust Anti-Inflammatory Activity and Suitable for Topical Pulmonary Administration

Published:2015-01-09 Issue:3 Volume:352 Page:559-567
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Moretto Nadia,Caruso Paola,Bosco Raffaella,Marchini Gessica,Pastore Fiorella,Armani Elisabetta,Amari Gabriele,Rizzi Andrea,Ghidini Eleonora,De Fanti Renato,Capaldi Carmelida,Carzaniga Laura,Hirsch Emilio,Buccellati Carola,Sala Angelo,Carnini Chiara,Patacchini Riccardo,Delcanale Maurizio,Civelli Maurizio,Villetti Gino,Facchinetti Fabrizio

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference39 articles.

1. TCR- and CD28-Mediated Recruitment of Phosphodiesterase 4 to Lipid Rafts Potentiates TCR Signaling

2. Nonredundant Function of Phosphodiesterases 4D and 4B in Neutrophil Recruitment to the Site of Inflammation

3. Novel Class of Benzoic Acid Ester Derivatives as Potent PDE4 Inhibitors for Inhaled Administration in the Treatment of Respiratory Diseases

4. Isolation and characterization of cGMP phosphodiesterase from bovine rod outer segments;Baehr;J Biol Chem,1979

5. Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New quinoline-based PDE4 inhibitors through GSK-256066 fragment-based elaboration;Journal of Molecular Structure;2024-01

2. The Molecular Blueprint for Chronic Obstructive Pulmonary Disease (COPD): A New Paradigm for Diagnosis and Therapeutics;Oxidative Medicine and Cellular Longevity;2023-12-21

3. Drug repurposing and structure-based discovery of new PDE4 and PDE5 inhibitors;European Journal of Medicinal Chemistry;2023-12

4. Modulation of Human Dendritic Cell Functions by Phosphodiesterase-4 Inhibitors: Potential Relevance for the Treatment of Respiratory Diseases;Pharmaceutics;2023-08-31

5. Carboxyamidotriazole ameliorates inflammation in experimental allergic asthma by inhibiting the expression of phosphodiesterase 4;2023-07-17